News
Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 22, 2019
NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative...
-
Jan 11, 2019Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS
NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
-
Jan 3, 2019
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today...
-
Dec 27, 2018
NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a...
-
Dec 26, 2018BrainStorm has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute, currently supporting the Phase 3 ALS Trial, to Produce NurOwn®
NEW YORK and BOSTON, Dec. 26, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases,...
-
Dec 17, 2018U.S. Phase 2 Study to Begin in First Quarter of 2019
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
-
Dec 4, 2018Poster highlights enrichment strategies for clinical trials in ALS
NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
-
Nov 19, 2018
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
-
Nov 7, 2018Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial
NEW YORK and PETACH TIKVAH, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics...
-
Oct 29, 2018BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate UpdateHighlights Scientific Advances and Continued Progress for NurOwn® in ALS Towards U.S. FDA Approval;
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today...
-
Oct 17, 2018Conference Call and Live Webcast at 8:30am Eastern Time
NEW YORK and PETACH TIKVAH, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
-
Oct 4, 2018Translational Insights Support NurOwn® as a Best-In-Class Strategy in ALS
NEW YORK and PETACH TIKVAH, Israel, Oct. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics...
-
Oct 3, 2018NurOwn® to be Featured at NEALS and Cell & Gene Meeting on the Mesa Conferences
NEW YORK and PETACH TIKVAH, Israel, Oct. 03, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative adult stem cell therapeutics for...
-
Sep 13, 2018
NEW YORK and PETACH TIKVAH, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative...
-
Sep 12, 2018
NEW YORK and PETACH TIKVAH, Israel, Sept. 12, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for debilitating...
-
Sep 5, 2018Presentation and Live Webcast on Thursday, September 6th, 2.10pm ET
NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
-
Sep 4, 2018BrainStorm Appoints Arturo Araya as Chief Commercial Officer
NEW YORK and PETACH TIKVAH, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative...
-
Aug 29, 2018
NEW YORK and PETACH TIKVAH, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
-
Aug 23, 2018
NEW YORK, and PETACH TIKVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative...
-
Jul 25, 2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has...
-
Jul 23, 2018Conference Call and Webcast at 8.30am ET Today
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the second quarter and...
-
Jul 17, 2018Conference Call and Live Webcast at 8.30am ET
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the second quarter ended...
-
Jul 5, 2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has received a Decision to Grant...
-
Jul 2, 2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell and...
-
Jun 28, 2018Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Joseph Petroziello as vice...
Tools
Investors
- Overview
- News
- Events & Presentations
- Stock Information
- Financial Reports & Filings
- Corporate Governance